Cardiovascular Disorders

Dyslipidemia

Clinical Overview and Exam Mastery Guide covering LDL-centered risk reduction, statin-first treatment, non-statin escalation, and hypertriglyceridemia strategy.

Primary Target
LDL cholesterol
First-Line
Statin therapy
Escalation
Ezetimibe then PCSK9
TG Warning
At least 500 mg/dL risk

Atherosclerosis Context

Atherosclerotic plaque within artery

LDL-driven plaque formation underpins dyslipidemia-related ASCVD risk.

1. What Is Dyslipidemia?

Dyslipidemia refers to abnormal lipid levels that increase atherosclerotic cardiovascular disease risk.

LDL (bad cholesterol) HDL (good cholesterol) Triglycerides
LDL is the primary treatment target.

2. Pathophysiology

Step 1: Excess LDL penetrates arterial wall
Step 2: LDL oxidation and inflammation
Step 3: Atherosclerotic plaque formation
Step 4: Plaque rupture may lead to ACS

LDL to ASCVD Pathway Diagram

Elevated LDL Retention in intima Oxidation + inflammation Foam cell cascade Atherosclerotic plaque Progressive lumen narrowing Plaque rupture -> ACS risk

3. Risk Assessment

Use ASCVD Risk Estimator to guide statin need and treatment intensity.

Assess

  • 10-year ASCVD risk
  • Need for statin therapy
  • Intensity of treatment

High-Risk Groups

  • Clinical ASCVD
  • LDL at least 190 mg/dL
  • Diabetes age 40 to 75
  • Elevated 10-year ASCVD risk

4. First-Line Therapy: Statins

Statins are the cornerstone of dyslipidemia treatment.

Intensity Common Regimens Typical Use
High-intensity Atorvastatin 40 to 80 mg, Rosuvastatin 20 to 40 mg Very high risk, LDL at least 190, secondary prevention
Moderate-intensity Lower atorvastatin/rosuvastatin doses, simvastatin, pravastatin Diabetes, intermediate risk, statin initiation in many primary settings

A. Statins

  • MOA: inhibit HMG-CoA reductase and lower hepatic cholesterol synthesis
  • Increase LDL receptor expression and LDL clearance
  • Benefits: lower LDL, reduce cardiovascular events, reduce mortality
  • Major side effects: myopathy, rare rhabdomyolysis, elevated liver enzymes, rare new-onset diabetes
  • Contraindications: active liver disease, pregnancy, breastfeeding

5. Non-Statin Therapy

Use when statin intolerance exists, LDL remains above goal, or risk is very high.

B. Ezetimibe

  • MOA: inhibits NPC1L1 transporter and lowers intestinal cholesterol absorption
  • Benefit: LDL reduction, especially as statin add-on
  • Side effects: usually mild GI symptoms
  • Contraindication: severe liver disease when combined with statin

C. PCSK9 Inhibitors (Alirocumab, Evolocumab)

  • MOA: inhibit PCSK9 and prevent LDL receptor degradation
  • Benefits: large LDL reduction and lower CV events
  • Side effects: injection-site reactions, flu-like symptoms
  • Contraindication: hypersensitivity

D. Bempedoic Acid

  • MOA: ATP-citrate lyase inhibition upstream of statins
  • Benefit: LDL lowering, useful in statin intolerance
  • Side effects: hyperuricemia, rare tendon rupture
  • Contraindication/caution: gout history

E. Fibrates (Fenofibrate, Gemfibrozil)

  • MOA: PPAR-alpha activation increases lipoprotein lipase activity
  • Primary use: severe hypertriglyceridemia
  • Side effects: myopathy risk (higher with statins), gallstones
  • Contraindications: severe liver disease, severe renal impairment

F. Omega-3 Fatty Acids

  • MOA: reduce hepatic triglyceride synthesis
  • Use: high triglycerides
  • Side effects: GI upset, fishy taste

6. Hypertriglyceridemia

When TG at least 500 mg/dL

  • Pancreatitis risk increases
  • Treat with fibrates or omega-3 therapy

ASCVD Context

  • Statins still required for overall ASCVD prevention

7. Treatment Strategy Summary

Step 1: Start high-intensity statin for high LDL/high risk
Step 2: Reassess lipid panel in 4 to 12 weeks
Step 3: Add ezetimibe if LDL remains above goal
Step 4: Add PCSK9 inhibitor for very high-risk persistent elevation

Management Recap Drill

1: Assess ASCVD risk profile
2: Start correct statin intensity
3: Recheck lipids in 4 to 12 weeks
4: Add ezetimibe if LDL not controlled
5: Add PCSK9 inhibitor for very high-risk persistent LDL elevation
6: Treat triglycerides when at least 500 to prevent pancreatitis

Visual Algorithm Placeholder

[Insert Dyslipidemia Treatment Algorithm Flowchart Here During UI Integration]

Guideline References

ACC/AHA Guideline on Blood Cholesterol Management

https://www.acc.org/guidelines
These guidelines inform statin intensity, ASCVD risk assessment, non-statin use, and treatment thresholds.

Image Attribution (Wikimedia Commons)

  • Atheroma illustration - Blausen.com staff, CC BY 3.0

8. Common Exam Traps

Statins are first-line in most dyslipidemia treatment pathways.
LDL at least 190 mg/dL generally requires high-intensity statin independent of calculated risk.
Diabetes age 40 to 75 usually requires at least moderate-intensity statin.
Statins are contraindicated in pregnancy and breastfeeding.
Fibrates primarily target high triglycerides, not LDL.

9. Quick Revision Summary

Must Remember

  • LDL is the primary treatment target
  • Statins reduce mortality and events
  • Add ezetimibe before PCSK9 in common escalation pathways
  • TG at least 500 means pancreatitis prevention priority
  • Monitor liver-related symptoms and adverse effects clinically

Practice Questions Placeholder

  • Topic: Dyslipidemia
  • Subtopics: statins, non-statin agents, ASCVD risk, hypertriglyceridemia, treatment intensification